Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering Guaifenesin

Client Email

Product

Guaifenesin
Ethyltriphenylphosphonium Bromide
Guaiacol
US Patents

PharmaCompass Sponsored Ads

Contact Supplier

Granules Guaifenesin

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Guaifenesin

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

46 API Suppliers, 18 USDMF, 9 CEP/COS, 3 JDMF, 3 EU WC, 4 KDMF, 18 NDC API, 26 Listed Suppliers, $ API Reference Price

46 API Suppliers
18 USDMF
9 CEP/COS
3 JDMF
3 EU WC
4 KDMF
18 NDC API
26 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

4 Drugs in Development

4 Drugs in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

FINISHED DOSAGE FORMULATIONS

186 FDF Dossiers, 51 FDA Orange Book, 5 Europe, 64 Canada, 23 South Africa, 43 Listed Dossiers

186 FDF Dossiers
51 FDA Orange Book
5 Europe
64 Canada
23 South Africa
43 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;ORAL - 200MG/5ML;2.5MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1.2GM, TABLET, EXTENDED RELEASE;ORAL - 600MG, TABLET, EXTENDED RELEASE;ORAL - 1.2GM;120MG, TABLET, EXTENDED RELEASE;ORAL - 600MG;60MG, TABLET, EXTENDED RELEASE;ORAL - 30MG;600MG, TABLET, EXTENDED RELEASE;ORAL - 60MG;1.2GM, SOLUTION;ORAL - 200MG/5ML;2.5MG/5ML;30MG/5ML

SOLUTION;ORAL - 200MG/5ML;2.5MG/5ML
TABLET, EXTENDED RELEASE;ORAL - 1.2GM
TABLET, EXTENDED RELEASE;ORAL - 600MG
TABLET, EXTENDED RELEASE;ORAL - 1.2GM;120MG
TABLET, EXTENDED RELEASE;ORAL - 600MG;60MG
TABLET, EXTENDED RELEASE;ORAL - 30MG;600MG
TABLET, EXTENDED RELEASE;ORAL - 60MG;1.2GM
SOLUTION;ORAL - 200MG/5ML;2.5MG/5ML;30MG/5ML

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Evonik, 12 Rochem International Inc, 23 SPI Pharma, 2 Seqens, 19 DKSH, 2 Jai Radhe Sales, 3 Pharm-RX Chemical, 13 Boai NKY Pharmaceuticals Ltd, 17 Gangwal Healthcare, 18 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 19 Actylis, 4 Aeon Procare, 3 Alcedo Pharmachem, 11 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 40 BASF, 2 Bioplus Life Sciences, 4 Clariant, 16 Corel Pharma Chem, 6 DFE Pharma, 4 Finar, 16 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 33 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 5 Lubrizol Life Science Health, 23 Microlex e.U, 3 Nanjing Bold Chemical, 2 Nomisma Healthcare, 5 Novo Excipients, 4 Pharmatrans-Sanaq, 11 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 56 Roquette, 19 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 3 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 3 The Dow Chemical Company, 4 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 3 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

128 Fillers, Diluents & Binders, 76 Thickeners and Stabilizers, 65 Coating Systems & Additives, 65 Solubilizers, 59 Direct Compression, 50 Taste Masking, 47 Topical, 46 Controlled & Modified Release, 45 Disintegrants & Superdisintegrants, 42 Parenteral, 37 Film Formers & Plasticizers, 37 Granulation, 30 Lubricants & Glidants, 24 Chewable & Orodispersible Aids, 21 Co-Processed Excipients, 20 Emulsifying Agents, 15 Rheology Modifiers, 14 API Stability Enhancers, 13 Surfactant & Foaming Agents, 9 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

128 Fillers, Diluents & Binders
76 Thickeners and Stabilizers
65 Coating Systems & Additives
65 Solubilizers
59 Direct Compression
50 Taste Masking
47 Topical
46 Controlled & Modified Release
45 Disintegrants & Superdisintegrants
42 Parenteral
37 Film Formers & Plasticizers
37 Granulation
30 Lubricants & Glidants
24 Chewable & Orodispersible Aids
21 Co-Processed Excipients
20 Emulsifying Agents
15 Rheology Modifiers
14 API Stability Enhancers
13 Surfactant & Foaming Agents
9 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

45 NEWS #PharmaBuzz

45 NEWS #PharmaBuzz

MARKET PLACE

25 APIs

25 APIs

PATENTS & EXCLUSIVITIES

3 US Patents

3 US Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 2 JP, 5 Others

1 EDQM
1 USP
2 JP
5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 13 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

3 All

01 3SOVEREIGN PHARMS

filter Patent Number Reset all filters

3 All

01 19549907

02 19808431

03 110105324

filter API Patent Reset all filters

3 All

01 3Y

filter FDF Patent Reset all filters

3 All

01 3Y

filter Expiration Date Reset all filters

3 All

01 32035-11-13

Atman Guaifenesin

Product Main Page

01

SOVEREIGN PHARMS

GUAIFENESIN; HYDROCODONE BITARTRATE

AAPS 2024

Not Confirmed

SOVEREIGN PHARMS

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-11-13

GUAIFENESIN; HYDROCODONE BITARTRATE

US Patent Number : 9549907

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205474

Patent Use Code : U-2023

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-11-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

SOVEREIGN PHARMS

GUAIFENESIN; HYDROCODONE BITARTRATE

AAPS 2024

Not Confirmed

SOVEREIGN PHARMS

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-11-13

GUAIFENESIN; HYDROCODONE BITARTRATE

US Patent Number : 9808431

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205474

Patent Use Code : U-2023

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-11-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

SOVEREIGN PHARMS

GUAIFENESIN; HYDROCODONE BITARTRATE

AAPS 2024

Not Confirmed

SOVEREIGN PHARMS

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2035-11-13

GUAIFENESIN; HYDROCODONE BITARTRATE

US Patent Number : 10105324

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205474

Patent Use Code : U-2023

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-11-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?